Micromolded or 3-D printed pulsatile release vaccine formulations

• US 10,300,136 B2
• Filed: 12/16/2014
• Issued: 05/28/2019
• Est. Priority Date: 12/16/2013
• Status: Active Grant

• Current Assignee: Tokitae LLC (Intellectual Ventures LLC), Massachusetts Institute of Technology
• Original Assignee: Tokitae LLC (Intellectual Ventures LLC), Massachusetts Institute of Technology
• Inventors: Jaklenec, Ana, Gates, William, Welkhoff, Philip A., Nikolic, Boris, Wood, Lowell L., Langer, Robert S., Nguyen, Thanh Duc, Tzeng, Stephany Yi, Norman, James J., McHugh, Kevin
• Primary Examiner(s): Blumel, Benjamin P
• Application Number:
  US14/572,631
• Publication Number:
  US 20150165020A1
• Time in Patent Office: 1,624 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/6093 Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 33/02 Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C12N 2770/32634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.

Claims

1. A polymeric device comprising a polymeric shell and at least one discrete region comprising a therapeutic, prophylactic, nutraceutical, or diagnostic agent, optionally in combination with a stabilizing excipient, wherein the shell and discrete regions are formed from successive layers of polymeric particles bonded together by solvent and/or temperature by three dimensional printing or micromolding.

2. The polymeric device of claim 1 formed by three dimensional printing or micromolding of a biocompatible polymer, the device comprising a polymeric shell and one or more discrete regions comprising antigen, optionally in combination with a stabilizing excipient for the antigen, wherein an effective amount of the antigen is released in two or more time periods to elicit an immune response with insufficient antigen release between the release periods to elicit an immune response in vivo.

3. The device of claim 2, wherein the device is made by three dimensional printing.

4. The device of claim 2 further comprising an effective amount of antigen to elicit an immune response in vivo which is present in a stabilizing excipient, on the surface of the device, or mixed with the polymer of the device.

5. The device of claim 2, comprising a stabilizing excipient selected from the group consisting of sugars, oils, lipids, and carbohydrates.

6. The device of claim 2, wherein the antigen elicits an immune response to an infectious agent or to a tumor.

7. The device of claim 6, wherein the infectious agent is a virus, bacteria, fungus or protozoan.

8. The device of claim 7, wherein the virus is selected from the group consisting of polio, influenza, hepatitis, rotavirus, measles, mumps, rubella, and varicella.

9. The device of claim 7, wherein the bacteria is selected from the group consisting of Corynebacterium diphtheriae, Bordetella pertussis, Clostridium tetani, Streptococcus pneumonia (Pneumococcus), and Neisseria meningitidis (Meningococcus).

10. The device of claim 6, wherein the antigen is a tumor antigen selectively eliciting a T cell response to a tumor.

11. The device of claim 2, wherein the polymer is biodegradable by hydrolysis.

12. The device of claim 2 providing release at intervals of between ten and ninety days.

13. The device of claim 2 wherein the antigen is encapsulated in polymeric particles in the form of microparticles, microcapsules, or microspheres.

14. The device of claim 2, wherein the device is injectable.

15. The device of claim 2, wherein the device is implantable.

16. The device of claim 2, wherein the device can be applied to a mucosal surface selected from the group consisting of nasal, pulmonary, oral, vaginal and rectal.

17. The device of claim 5, wherein the stabilizing excipient comprises sugar, wherein the sugar is selected from the group consisting of sucrose, trehalose, and combinations thereof.

18. The device of claim 2, wherein the stabilizing excipient comprises monosodium glutamate (MSG).

19. The device of claim 2, wherein the stabilizing excipient comprises magnesium chloride (MgCl₂).

20. The device of claim 17, wherein the sugar comprises sucrose.

21. The device of claim 2 providing release at intervals of between 30 and 60 days.

22. The device of claim 2, wherein the agent is released in at least three time periods at intervals of between ten and ninety days.

23. The device of claim 2, wherein the agent is released in at least four time periods at intervals of between ten and ninety days.

24. The device of claim 2, further comprising a buffering agent.

25. The device of claim 24, wherein the buffering agent is selected from the group consisting of magnesium hydroxide, aluminum hydroxide, and myristic acid.